Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]PRNewsWire • 11/07/23
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & MoreZacks Investment Research • 11/06/23
Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/31/23
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?The Motley Fool • 10/31/23
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial ResistancePRNewsWire • 10/30/23
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a RowPRNewsWire • 10/23/23
Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.Business Wire • 10/10/23
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 BillionInvestors Business Daily • 10/02/23